General Information of Drug (ID: DM4K7GQ)

Drug Name
Erythromycin Drug Info
Synonyms
Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1]
Acute gonococcal cervicitis Approved [1]
Acute otitis media AB00 Approved [1]
Bacteremia 1A73 Approved [1]
Bacterial infection 1A00-1C4Z Approved [2]
Cholangitis Approved [1]
Gastroparesis DA41.00 Approved [1]
Hepatic coma Approved [1]
Inclusion conjunctivitis Approved [1]
Legionnaires' disease Approved [1]
Listeriosis Approved [1]
Mycoplasma pneumoniae pneumonia Approved [1]
Preterm premature rupture of the membranes Approved [1]
Staphylococcus aureus infection Approved [1]
Streptococcal pneumonia Approved [1]
Syphilis Approved [1]
Urinary tract infection GC08 Approved [1]
Erythema ME64.0 Investigative [1]
Pneumonia caused by chlamydia Investigative [1]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
12560
ChEBI ID
CHEBI:42355
CAS Number
CAS 114-07-8
TTD Drug ID
DM4K7GQ
VARIDT Drug ID
DR00050
INTEDE Drug ID
DR0614
ACDINA Drug ID
D00241

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Telithromycin DMZ4P3A Bacterial infection 1A00-1C4Z Approved [25]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [26]
Dirithromycin DM0D9YJ Bacterial infection 1A00-1C4Z Approved [27]
Clindamycin DM15HL8 Acne vulgaris ED80 Approved [26]
Zithromax DMN4H2O Syphilis infection 1A6Z Approved [28]
Troleandomycin DMUZNIG Bacterial infection 1A00-1C4Z Approved [29]
Retapamulin DM9JXB7 Impetigo 1B72 Approved [30]
Dalfopristin DM4LTKV Bacterial infection 1A00-1C4Z Approved [31]
Tedizolid DMG2SKR Skin infection 1F28-1G0Z Approved [32]
Gentamicine sulfate DMBT7MI Bacterial infection 1A00-1C4Z Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [34]
Methotrexate DM2TEOL Anterior urethra cancer Approved [35]
Folic Acid DMEMBJC Colorectal carcinoma Approved [36]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [37]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [38]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [39]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [40]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [41]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [42]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [44]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Folic Acid DMEMBJC Colorectal carcinoma Approved [47]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [46]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [46]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [48]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [46]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [49]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [51]
Methotrexate DM2TEOL Anterior urethra cancer Approved [52]
Folic Acid DMEMBJC Colorectal carcinoma Approved [53]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [54]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [55]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [56]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [57]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [56]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [58]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [60]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [61]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [62]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [63]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [64]
Aciclovir DMYLOVR Genital herpes 1A94 Approved [65]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [66]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [67]
Theophylline DMRJFN9 Bronchitis CA20 Approved [4]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [69]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [70]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [71]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [72]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [70]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [73]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [74]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [75]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [75]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [76]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [77]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [78]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [79]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [80]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [81]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [82]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [83]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [84]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [78]
Verapamil DMA7PEW Angina pectoris BA40 Approved [85]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [123]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [124]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [125]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [126]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [127]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [127]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [128]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [129]
Capsaicin DMGMF6V Back pain ME84.Z Approved [130]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [131]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [86]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [87]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [88]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [89]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [90]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [91]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [83]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [92]
Verapamil DMA7PEW Angina pectoris BA40 Approved [93]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [94]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [95]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [96]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [97]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [98]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [92]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [99]
Estrone DM5T6US Acne vulgaris ED80 Approved [100]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [101]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [102]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [103]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [104]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [105]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [106]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [107]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [108]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [109]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [110]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [111]
Verapamil DMA7PEW Angina pectoris BA40 Approved [112]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [107]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [123]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [124]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [129]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [129]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [132]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [133]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [134]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [135]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [137]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [113]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [107]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [107]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [107]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [114]
Verapamil DMA7PEW Angina pectoris BA40 Approved [115]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [107]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [107]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [107]
Metronidazole DMTIVEN Abscess Approved [116]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [117]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [97]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [92]
Estrone DM5T6US Acne vulgaris ED80 Approved [100]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [118]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [119]
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [120]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [121]
Theophylline DMRJFN9 Bronchitis CA20 Approved [120]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [122]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [14]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [14]
Benzphetamine DMIJATC Obesity 5B81 Approved [14]
Ethylmorphine DM0YROF Discovery agent N.A. Investigative [14]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dicloxacillin DM8EU0Z Bacterial infection 1A00-1C4Z Approved [138]
Ergonovine DM0VEC1 Postpartum haemorrhage JA43 Approved [18]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [139]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [140]
Mizolastine DM1FDN8 Allergic rhinitis CA08.0 Approved [141]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [142]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [143]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [144]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [145]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [146]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [147]
Quinidine DMLPICK N. A. N. A. Approved [148]
Verapamil DMA7PEW Angina pectoris BA40 Approved [149]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [150]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [151]
Propranolol DM79NTF Angina pectoris BA40 Approved [152]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [153]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [154]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [150]
Cisapride DMY7PED Gastroesophageal reflux disease DA22.Z Approved [155]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear protein 1 (NUPR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [156]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [17]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [158]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [160]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Serine protease hepsin (HPN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Selenium DM25CGV N. A. N. A. Approved [161]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [157]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [162]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [135]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [163]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [158]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Methotrexate DM2TEOL Anterior urethra cancer Approved [164]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [165]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Asparagine synthetase (ASNS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [166]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [167]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [168]
Methotrexate DM2TEOL Anterior urethra cancer Approved [169]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [17]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [170]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [171]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lanosterol synthase (LSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [172]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [173]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [174]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [157]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Inhibin beta E chain (INHBE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [158]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [174]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [157]
Panobinostat DM58WKG Chronic graft versus host disease Approved [175]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Acid ceramidase (ASAH1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [176]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [17]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [177]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [17]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [178]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [157]
Haloperidol DM96SE0 Delirium Approved [17]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [135]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
Clozapine DMFC71L Schizophrenia 6A20 Approved [157]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein DEPP1 (DEPP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [17]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [179]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [180]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [17]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transgelin (TAGLN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [181]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [158]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Methotrexate DM2TEOL Anterior urethra cancer Approved [182]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [157]
Quercetin DM3NC4M Obesity 5B81 Approved [159]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [183]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [184]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aldosterone DM9S2JW Hypertension BA00-BA04 Approved [185]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [186]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
Potassium Chloride DMMTAJC Hypokalemia 5C77 Approved [187]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [188]
Mitotane DMU1GX0 Adrenocortical carcinoma 2D11.Z Approved [189]
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [21]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [190]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [191]
Testosterone DM7HUNW Hot flushes GA30 Approved [185]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [192]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [19]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [19]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [193]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [192]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [19]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [194]
Gefitinib DM15F0X Colon adenocarcinoma Approved [192]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [195]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [192]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein c-Fos (FOS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [196]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [197]
Verapamil DMA7PEW Angina pectoris BA40 Approved [198]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [199]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [198]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [200]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [201]
Methotrexate DM2TEOL Anterior urethra cancer Approved [202]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [203]
Quercetin DM3NC4M Obesity 5B81 Approved [204]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [205]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [206]
Allopurinol DMLPAOB Gout FA25 Approved [207]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [208]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [209]
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [210]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [211]
Flucloxacillin DMNUWST Bacterial infection 1A00-1C4Z Approved [212]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [213]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [214]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [206]
Allopurinol DMLPAOB Gout FA25 Approved [215]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [216]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [213]
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [217]
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [213]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [171]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [210]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [210]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By L-selectin (SELL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [218]
Meloxicam DM2AR7L Arthritis FA20 Approved [218]
Methotrexate DM2TEOL Anterior urethra cancer Approved [164]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [219]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [218]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [220]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [218]
Phenylbutazone DMAYL0T Chronic pain MG30 Approved [218]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [135]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [218]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By E-selectin (SELE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [221]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [222]
Methotrexate DM2TEOL Anterior urethra cancer Approved [223]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [224]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [225]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [226]
Tibolone DM78XFG Anabolic metabolism 5C50-5C8Z Approved [227]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [228]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [229]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [230]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [161]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [210]
Methotrexate DM2TEOL Anterior urethra cancer Approved [164]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [210]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [219]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [231]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [210]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [210]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [210]
Pyrimethamine DM5X7VY Malaria 1F40-1F45 Approved [210]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [231]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [232]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [233]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [234]
Omacetaxine mepesuccinate DMPU2WX Adult acute monocytic leukemia Approved [232]
Valsartan DMREUQ6 Chronic heart failure BD1Z Approved [235]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [236]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [237]
Napabucasin DMDZ6Q3 Colorectal cancer 2B91.Z Phase 3 [238]
Fenretinide DMRD5SP Macular degeneration 9B78.3 Phase 3 [239]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Caspase-3 (CASP3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [240]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [241]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [242]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [243]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [244]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [245]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [246]
Mannitol DMSCDY9 Bronchiectasis CA24 Approved [247]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [248]
Aprepitant DM053KT Depression 6A70-6A7Z Approved [249]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Angina pectoris BA40 Approved [250]
Atenolol DMNKG1Z Angina pectoris BA40 Approved [250]
Quinidine DMLPICK N. A. N. A. Approved [18]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [180]
Bupivacaine DM4PRFC Anaesthesia 9A78.6 Approved [251]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [252]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
Mepivacaine DMH2NMY Analgesia MB40.8 Approved [251]
Mitoxantrone DMM39BF Acute myelogenous leukaemia 2A41 Approved [253]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [253]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [161]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [171]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [254]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [255]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [256]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [257]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [258]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [236]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Halothane DM80OZ5 Anaesthesia 9A78.6 Approved [18]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [259]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [260]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [18]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [18]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [18]
Gefitinib DM15F0X Colon adenocarcinoma Approved [261]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [262]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [261]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [261]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [4]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [5]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [10]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [13]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DEIZLTN CP4FB_HUMAN Substrate [14]
Beta-glucuronidase (uidA) DE7IQ34 A0A2A5L2J1_LACRH Substrate [15] , [16]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Gene/Protein Processing [17]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Drug Response [18]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Gene/Protein Processing [17]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [19]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [20]
Cytochrome P450 11B2, mitochondrial (CYP11B2) OTIOLWYN C11B2_HUMAN Gene/Protein Processing [21]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [22]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Biotransformations [23]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Gene/Protein Processing [24]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Gene/Protein Processing [17]

References

1 Erythromycin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1456).
3 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
4 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
5 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
6 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
7 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
8 Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
9 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
10 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
11 Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
12 Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
13 Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
14 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
15 Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
16 Degradation of various insecticides in cooked eggs during in vitro human digestion. Environ Pollut. 2018 Dec;243(Pt A):437-443.
17 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
18 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
19 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
20 Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics. Toxicol In Vitro. 2019 Aug;58:51-59. doi: 10.1016/j.tiv.2019.03.015. Epub 2019 Mar 12.
21 Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):142-53.
22 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
23 Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004 Dec;32(12):1434-45. doi: 10.1124/dmd.104.001313. Epub 2004 Sep 21.
24 The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006 Jan 20;218(1):30-8. doi: 10.1016/j.tox.2005.09.014. Epub 2005 Nov 16.
25 An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
26 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
27 Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
28 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
29 Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
30 Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
31 The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
32 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
33 The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
34 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
35 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
36 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
37 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
38 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
39 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
40 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
41 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
42 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
43 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
44 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
45 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
46 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
47 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
48 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
49 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
50 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
51 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
52 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
53 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
54 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
55 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
56 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
57 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
58 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
59 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
60 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
61 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
62 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
63 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
64 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
65 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
66 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
67 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
68 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
69 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
70 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
71 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
72 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
73 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
74 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
75 FDA Drug Development and Drug Interactions
76 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
77 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
78 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
79 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
80 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
81 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
82 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
83 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
84 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
85 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
86 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
87 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
88 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
89 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
90 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
91 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
92 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
93 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
94 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
95 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
96 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
97 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
98 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
99 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
100 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
101 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
102 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
103 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
104 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
105 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
106 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
107 Drug Interactions Flockhart Table
108 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
109 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
110 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
111 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
112 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
113 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
114 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
115 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
116 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
117 Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
118 Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
119 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
120 Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
121 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
122 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
123 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
124 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
125 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
126 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
127 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
128 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
129 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
130 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
131 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
132 Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
133 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
134 Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
135 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
136 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
137 Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
138 Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother. 2004 Feb;53(2):174-9. doi: 10.1093/jac/dkh056. Epub 2004 Jan 16.
139 Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012 Apr;26(4):1535-48. doi: 10.1096/fj.11-198184. Epub 2011 Dec 23.
140 The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc. 2005 Jul-Aug;26(4):292-8.
141 Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55 Suppl 64:17-27. doi: 10.1034/j.1398-9995.2000.00803.x.
142 Cytokine mRNA profiles in cultured human skin component cells exposed to various chemicals: a simulation model of epicutaneous stimuli induced by skin barrier perturbation in comparison with that due to exposure to haptens or irritant. J Dermatol Sci. 2001 Jun;26(2):85-93. doi: 10.1016/s0923-1811(00)00165-1.
143 Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy. Rom J Gastroenterol. 2003 Jun;12(2):91-5.
144 Some non-sensitizers upregulate CD54 expression by activation of the NLRP3 inflammasome in THP-1 cells. J Toxicol Sci. 2019;44(3):213-224. doi: 10.2131/jts.44.213.
145 Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
146 The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene. 2008 Apr 17;27(18):2648-55. doi: 10.1038/sj.onc.1210891. Epub 2007 Dec 3.
147 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
148 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
149 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
150 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
151 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
152 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
153 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
154 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
155 The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem. 2002 Feb 15;277(7):4989-98. doi: 10.1074/jbc.M107345200. Epub 2001 Dec 10.
156 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
157 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
158 In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
159 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
160 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
161 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
162 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
163 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
164 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
165 Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
166 Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
167 Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
168 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
169 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
170 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
171 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
172 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
173 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
174 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
175 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
176 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
177 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
178 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
179 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
180 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
181 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
182 Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
183 Differentiation of human embryonic stem cells into smooth muscle cells in adherent monolayer culture. Biochem Biophys Res Commun. 2006 Dec 15;351(2):321-7. doi: 10.1016/j.bbrc.2006.09.171. Epub 2006 Oct 17.
184 Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther. 2007 Jan;6(1):70-81. doi: 10.1158/1535-7163.MCT-06-0125.
185 [Association study between a polymorphism of aldosterone synthetase gene and the pathogenesis of polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi. 2003 Feb;38(2):94-7.
186 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
187 Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008 Apr 28;584(2-3):424-34. doi: 10.1016/j.ejphar.2008.02.001. Epub 2008 Feb 12.
188 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
189 Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013 May 21;20(3):371-81.
190 Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol Scand Suppl. 2009;(189):14-21.
191 Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens. 2002 May;15(5):389-93. doi: 10.1016/s0895-7061(02)02256-2.
192 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
193 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
194 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
195 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
196 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
197 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
198 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
199 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
200 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
201 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
202 Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
203 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
204 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
205 Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008 Oct;9(10):1543-6. doi: 10.2217/14622416.9.10.1543.
206 Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010 Mar;11(3):349-56. doi: 10.2217/pgs.09.162.
207 HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9. doi: 10.1073/pnas.0409500102. Epub 2005 Mar 2.
208 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
209 HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013 Jul;54(7):1307-14. doi: 10.1111/epi.12217. Epub 2013 May 20.
210 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
211 Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002 Mar 30;359(9312):1121-2. doi: 10.1016/S0140-6736(02)08158-8.
212 HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.
213 HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013.
214 HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011 Mar 24;364(12):1134-43. doi: 10.1056/NEJMoa1013297.
215 Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011 May;21(5):303-7. doi: 10.1097/FPC.0b013e32834282b8.
216 A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
217 Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.
218 Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem. 2002 Oct 11;277(41):38212-21. doi: 10.1074/jbc.M205142200. Epub 2002 Jul 29.
219 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
220 Immunological consequences of thalidomide treatment in Sj?gren's syndrome. Ann Rheum Dis. 2006 Jan;65(1):112-4. doi: 10.1136/ard.2005.038406.
221 Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
222 Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc Res. 2003 Feb;57(2):563-71. doi: 10.1016/s0008-6363(02)00699-5.
223 Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum. 2004 Oct;50(10):3286-95. doi: 10.1002/art.20518.
224 Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab. 2003 Nov;88(11):5341-7. doi: 10.1210/jc.2003-030724.
225 Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H741-7. doi: 10.1152/ajpheart.01182.2005. Epub 2006 Mar 31.
226 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
227 Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
228 Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):481-90. doi: 10.1016/j.numecd.2008.10.003. Epub 2009 Jan 26.
229 Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 2001 Apr 1;97(7):1937-41. doi: 10.1182/blood.v97.7.1937.
230 Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1804-9. doi: 10.1161/01.ATV.0000176192.16951.9a. Epub 2005 Jul 7.
231 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
232 Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. J Exp Clin Cancer Res. 2019 Jul 15;38(1):308. doi: 10.1186/s13046-019-1295-8.
233 Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
234 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
235 Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PLoS One. 2012;7(6):e39930. doi: 10.1371/journal.pone.0039930. Epub 2012 Jun 29.
236 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
237 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
238 Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
239 The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res. 2005 Jun 15;11(12):4610-9.
240 Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
241 [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
242 Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
243 Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
244 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
245 Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
246 Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
247 Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
248 mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
249 Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
250 Additional gene variants reduce effectiveness of beta-blockers in the LQT1 form of long QT syndrome. J Cardiovasc Electrophysiol. 2004 Feb;15(2):190-9. doi: 10.1046/j.1540-8167.2004.03212.x.
251 Long QT 1 mutation KCNQ1A344V increases local anesthetic sensitivity of the slowly activating delayed rectifier potassium current. Anesthesiology. 2006 Sep;105(3):511-20. doi: 10.1097/00000542-200609000-00015.
252 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
253 Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
254 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
255 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
256 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
257 Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
258 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
259 Quercetin protected against isoniazide-induced HepG2 cell apoptosis by activating the SIRT1/ERK pathway. J Biochem Mol Toxicol. 2019 Sep;33(9):e22369. doi: 10.1002/jbt.22369. Epub 2019 Jul 23.
260 Drug-induced liver injury: Oltipraz and C2-ceramide intervene HNF-1/GSTA1 expression via JNK signaling pathway. J Appl Toxicol. 2021 Dec;41(12):2011-2020. doi: 10.1002/jat.4181. Epub 2021 May 6.
261 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
262 A Study of Gentianae Radix et Rhizoma Class Differences Based on Chemical Composition and Core Efficacy. Molecules. 2023 Oct 17;28(20):7132. doi: 10.3390/molecules28207132.